Canadian-developed Ebola vaccine on track for WHO approval
The European Medicines Agency has recommended a conditional marketing authorization for the rVSV-ZEBOV-GP vaccine, originally developed in Canada. This authorization is an important step towards the European Commission's decision on licensing and the World Health Organization (WHO) prequalification of the vaccine. Licensed doses are expected to be available mid-2020.
Key funders of the randomized control trial conducted by the government of Guinea and WHO in 2015 included the Public Health Agency of Canada, the Canadian Institutes of Health Research, Canada's International Development Research Centre and Global Affairs Canada. Noway's Ministry of Foreign Affairs as well as the Wellcome Trust, the UK government and Médecins Sans Frontières also helped to fund the studies’ volunteers, researchers, and health workers in Guinea.